JPRN-UMIN000016790已完成1 期
A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA) - A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer(RPN2siRNA)
ational Cancer Center0 个研究点目标入组 30 人开始时间: 2015年3月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients who meet the following conditions. a)Patients who received other investigational drug(s) within 4 weeks before enrollment b)Patients who received systemic therapy within 3 weeks before enrollment c)Patients who received surgery within 4 weeks before enrollment d)Patients who received radiation in wide area within 4 weeks before enrollment or received palliative radiation within 2 weeks before enrollment e)Patients who have received radiation to planned lesion of administration of investigational drug 2. Patients with brain metastasis, except for patients who have completed topical therapy and stopped treatment with glucocorticoid agents at least 4 weeks before enrollment. For these patients, stable disease must be confirmed by symptoms and the images at the time of enrollment compared to the one obtained at least 4 weeks before enrollment.. 3. Patients with systemic active infection. 4. Patients with active infection at planned lesions of administration of investigational drug. 5. Patients with allergy to local anesthetic 6. Patients with respiratory failure requiring oxygen inhalation therapy 7. Patients requiring anti-coagulant therapy 8. Patients with serious cardiovascular disease (congestive cardiac failure within 6 months before enrollment, history of unstable angina or myocardial infarction, or serious arrhythmia) 9. Patients with difficulty following the study procedures due to psychiatric disease or psychological symptoms 10. Patients who meet the following conditions. a)HBs-Ag positive (In case HBs-Ag is negative but HBs-Ab and/or HBc-Ab are/is positive, only HBV-DNA negative can be allowed to enroll.) b)HCV-Ab positive and/or HCV-RNA positive c)HIV-Ab positive 11. Pregnant or breast-feeding women, or women of child bearing potential who intend to become pregnant 12. Patients who should not participate in the study, as judged by the investigator(s)
研究者
相似试验
进行中（未招募）
1 期
Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patientsEUCTR2020-003299-42-PLPhilogen S.p.A.40
进行中（未招募）
1 期
Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patientsPatients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery according to the evaluation of a local interdisciplinary tumor board or who refuse surgery and for whom an histological evaluation is available according to international guidelinesMedDRA version: 20.0Level: PTClassification code 10004146Term: Basal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003299-42-DEPhilogen S.p.A.40
进行中（未招募）
不适用
A phase II study of L19IL2 injected directly into the tumor in patients with stage III/IV melanomaCancer- Patients with histopathologically-proven malignant melanoma with presence of measurable and injectable dermal or subcutaneous metastases either in clinical stage III or stage IVMedDRA version: 15.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014799-23-ATPhilogen S.p.A40
进行中（未招募）
不适用
A phase II study of L19IL2 injected directly into the tumor in patients with stage III/IV melanomaCancer- Patients with histopathologically-proven malignant melanoma with presence of measurable and injectable dermal or subcutaneous metastases either in clinical stage III or stage IVMedDRA version: 14.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014799-23-DEPhilogen S.p.A40
进行中（未招募）
不适用
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.Histologically-confirmed malignant melanoma of the skin with presence of injectable cutaneous and/or subcutaneous lesions either in clinical stage III or stage IV M1a.MedDRA version: 14.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001991-13-ITPHILOGEN S.P.A.20